Therapeutic drug monitoring of tobramycin: Once-daily versus twice-daily dosage schedules

Journal of Clinical Pharmacy and Therapeutics

Volumn 23, Issue 5, 1998, Pages 367-373

  Sanchez Alcaraz A ^a   Vargas, A ^a   Quintana, M B ^a   Rocher, A ^a   Querol, J M ^b   Poveda, J L ^b   Hermenegildo, M ^b  

^a HOSPITAL ARNAU DE VILANOVA   (Spain)

^b HOSPITAL LLUÍS ALCANYÍS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; TOBRAMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MONITORING; ENZYME IMMUNOASSAY; FEMALE; HEARING; HEARING LOSS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; MALE; NEPHROTOXICITY; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; CREATININE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HEARING LOSS; HUMANS; KIDNEY; MALE; MIDDLE AGED; TOBRAMYCIN;

EID: 0031697294     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1998.00174.x     Document Type: Article

References (12)

1. Nordström L, Ringsberg H, Cronberg S, Tjernström O, Walder M. (1990) Does administration of an amino-glycoside in a single daily close affect its efficancy and toxicity? . Journal of Antimicrobial Chemotherapy, 25, 159-173.
2. Kapusnic JE, Hackbarth CJ, Chmbers HF, Carpenter T, Sander ME. (1988) Single, large and daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. Journal of Infectious Diseases, 158, 7-12.
3. Vogelman BS, Criag WA. (1985) Postantibiotic effects. journal of Antimicrobial Chemotherapy, 15(Suppl. A), 37-46.
4. Tulkens PM. (1991) Pharmacokinetic and tioxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin. Journal of Antimicrobial Chemotherapy, 27(Suppl. C), 49-61.
5. Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P. (1993) Once- versus thrice-daily gentamicin in patients with serious infections. Lancet, 341, 335-339.
6. Ferriols-Lisart R, Alós-Almiñana M. (1996) Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. American Journal of Health-System Pharmacy, 53, 1141-1150.
7. Matthews SJ. (1995) Aminoglycosides. In: Schumacher GE, eds. Therapeutic Drug Monitoring. Norwallk: Appleton & Lange, pp. 237-294.
8. Blaser J, Stone B, Zinner SH. (1985) Efficacy of intermittent versus continuous administration of netilmicin in a new two-compartment in-vitro model. Antimicrobial Agents and Chemotherapy, 27, 343-349.
9. Barclay ML, Beeg FJ, Hickling KG. (1994) What is the evidence for once-daily aminoglycoside therapy? Clinical Pharmacokinetics, 27, 32-48.
10. Zhanel GG, Craig WA. (1994) Pharmacokinetics contributions to post-antibiotic effects: focus on aminoglycosides. Clinical Pharmacokinetics, 27, 377-392.
11. Rodman DP, Maxwell AJ, McKnight JT. (1994) Extended dosage intervals for aminoglycosides. American Journal of Hospital Pharmacy, 51, 2016-2021.
12. Parker SE, Davey PG. (1995) Once-daily aminoglycoside administration in Gram-negative sepsis: economic and practical aspects. Pharmaco-Economics, 7, 393-402.